Background The use of immune checkpoint inhibitors (ICIs) has become standard therapy in
many tumor sites. The aim of this study is to systematically review the literature to determine …

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …

Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …

In recent years, immunotherapy-based regimens have been included into the treatment's
algorithm of several cancer types. Programmed death-1 (PD-1) and cytotoxic T lymphocyte …

Targeting the immune system with immune checkpoint inhibitors (ICI) to treat cancer has
been lately adopted with a significant improvement of patients' survival. In parallel, the …

Immunotherapy based on immune checkpoint inhibitors (ICIs) represents a novel anticancer
treatment strategy. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 …

Background We investigated the association between adverse events (AEs) suspected to be
immune-related and health care resource utilization, costs, and mortality among patients …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have advanced the treatment of
metastatic melanoma by blocking immune system down-regulators enhancing T-cell …

Background Immune checkpoint inhibitors (ICIs) have been proposed as the standard first-
line and subsequent treatment for metastatic non-small cell lung cancer (NSCLC). This study …

Despite the use of first-line therapies like fluoropyrimidine and platinum-based cytotoxic
chemotherapy, gastric cancer (GC) continues to carry a poor prognosis. Recent subgroup …